In draft guidance, NICE fails to back Clovis's PARP inhibitor Rubraca
Despite the EMA’s endorsement of Clovis’s cancer treatment Rubraca last year, the UK’s cost-effectiveness watchdog NICE has recommended against the adoption of the drug in the National Health Service (NHS).
Rubraca is approved for use in the EU as monotherapy for the maintenance treatment of adult patients with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have relapsed after platinum-based chemotherapy. The drug was originally developed at Newcastle University, with a team involving researchers from the Northern Institute for Cancer Research and Cancer Research UK-funded scientists. It generated second-quarter sales of $33 million globally.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.